CAJ | 학술논문

目的评价单用格列美脲或联合二甲双胍控制不佳的2型糖尿病（T2DM）患者加用西格列汀的有效性和安全性。方法40例T2DM患者中20例接受格列美脲单药治疗（4 mg/d），20例接受格列美脲联合二甲双胍（1500 mg/d）治疗，两组患者加用西格列汀（100 mg/d）治疗16周。结果两组患者加用西格列汀16周后糖化血红蛋白（HbA1C）、空腹血糖（FPG）、餐后2 h血糖（2 h PG）显著降低（P＜0.01），空腹胰岛素（FIns）、稳态模型评估β细胞功能（HOMA-β）显著提高（P＜0.05），加用西格列汀后低血糖风险低，胃肠道不良反应少。结论格列美脲单用或联合二甲双胍控制不佳的T2DM患者加用西格列汀100 mg/d后，能有效控制血糖，改善β细胞功能，且耐受性良好。
목적평개단용격렬미뇨혹연합이갑쌍고공제불가적2형당뇨병（T2DM）환자가용서격렬정적유효성화안전성。방법40례T2DM환자중20례접수격렬미뇨단약치료（4 mg/d），20례접수격렬미뇨연합이갑쌍고（1500 mg/d）치료，량조환자가용서격렬정（100 mg/d）치료16주。결과량조환자가용서격렬정16주후당화혈홍단백（HbA1C）、공복혈당（FPG）、찬후2 h혈당（2 h PG）현저강저（P＜0.01），공복이도소（FIns）、은태모형평고β세포공능（HOMA-β）현저제고（P＜0.05），가용서격렬정후저혈당풍험저，위장도불량반응소。결론격렬미뇨단용혹연합이갑쌍고공제불가적T2DM환자가용서격렬정100 mg/d후，능유효공제혈당，개선β세포공능，차내수성량호。
Objective To evaluate the efficacy and safety of a treatment with sitagliptin in patients with type 2 diabetes who had inadequate glycemic control while on glimepiride alone or in combination with metformin. Methods Of these 40 patients,20 were on glimepiride monotherapy and 20 were on glimepiride plus metformin combination therapy. All patients were provided sitagliptin therapy for 16 weeks. Results After 16 weeks,HbA1C,FPG and 2 h PG were significantly reduced(P<0.01),while FIns and homeostasis model assessment-βwere significantly increased (P<0.05)by the addition of sitagliptin. Low incidence of hypoglycemia and less gastrointestinal adverse reactions were found in the addition of sitagliptin. Conclusion Sitagliptin 100 mg once daily may be able to significantly improve glycemic control and β-cell function in patients with type 2 diabetes who have inadequate glycemic control with glimepiride or glimepiride plus metformin therapy. The addition of sitagliptin is generally well tolerated.